A cellular oncogene is translocated to the Philadelphia chromosome in chronic myelocytic leukaemia
The DOI matches its Crossref record; 27 of the 27 references it cites were found in a registry or an index.
Abstract
The transforming genes of oncogenic retroviruses are homologous to a group of evolutionary conserved cellular onc genes. The human cellular homologue (c-abl) of the transforming sequence of Abelson murine leukaemia virus (A-MuL V) was recently shown to be located on chromosome 9. The long arm of this chromosome is involved in a specific translocation with chromosome 22, the Philadelphia translocation (Ph1), t(9; 22) (q34, q11), which occurs in patients with chronic myelocytic leukaemia (CML)3-5. Here we investigate whether the c-abl gene is included in this translocation. Using c-abl and v-abl hybridization probes on blots of somatic cell hybrids, positive hybridization is found when the 22q- (the Philadelphia chromosome), and not the 9q+ derivative of the translocation, is present in the cell hybrids. From this we conclude that in CML, c-abl sequences are translocated from chromosome 9 to chromosome 22q-. This finding is a direct demonstration of a reciprocal exchange between the two chromosomes and suggests a role for the c-abl gene in the generation of CML.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The importance of proto-oncogenes was further highlighted by discoveries that nonviral cancers frequently have genetic alterations in proto-oncogenes that activate them and drive oncogenesis—for example, mutations in H-ras or K-ras (76), gene amplification of c-myc (77), and chromosomal translocation/activation involving c-abl (78).”
From The Discovery of Reverse Transcriptase (2016) · cites this paper as [78]
Citations
Cites
ROWLEY, J. D. (1973) · Nature · doi:10.1038/243290a0 · Cited by 4,291
Human EJ bladder carcinoma oncogene is homologue of Harvey sarcoma virus ras gene
Parada, L. F., Tabin, C. J., Shih, C., & Weinberg, R. A. (1982) · Nature · doi:10.1038/297474a0 · Cited by 944
Der, C. J., Krontiris, T. G., & Cooper, G. M. (1982) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.79.11.3637 · Cited by 800
A physical map of the DNA regions flanking the rabbit β-globin gene
Jeffreys, A. (1977) · Cell · doi:10.1016/0092-8674(77)90119-2 · Cited by 644
Santos, E., Tronick, S. R., Aaronson, S. A., Pulciani, S., & Barbacid, M. (1982) · Nature · doi:10.1038/298343a0 · Cited by 623
Chang, E. H., Furth, M. E., Scolnick, E. M., & Lowy, D. R. (1982) · Nature · doi:10.1038/297479a0 · Cited by 587
Abelson murine leukaemia virus protein is phosphorylated in vitro to form phosphotyrosine
Witte, O. N., Dasgupta, A., & Baltimore, D. (1980) · Nature · doi:10.1038/283826a0 · Cited by 530
Goff, S. P., Gilboa, E., Witte, O. N., & Baltimore, D. (1980) · Cell · doi:10.1016/0092-8674(80)90554-1 · Cited by 470
Khan, P. M. (1971) · Archives of Biochemistry and Biophysics · doi:10.1016/s0003-9861(71)80007-3 · Cited by 344
Chromosomal localization of human cellular homologues of two viral oncogenes
Heisterkamp, N., Groffen, J., Stephenson, J. R., Spurr, N. K., Goodfellow, P. N., Solomon, E., Carritt, B., & Bodmer, W. F. (1982) · Nature · doi:10.1038/299747a0 · Cited by 303
Self-citation
Research works printed but not linked: 2
- Heisterkamp, N., Groffen, J. & Stephenson, J. R. J. molec. appl. Genet. (in the press).
- Ferguson-Smith, M. A. & Aitken, D. A. Cytogenet. Cell Genet. 22, 49–451 (1978).
Cited by
Items 501–600 of 1,000
Vascular Impact of Cancer Therapies: The Case of BTK (Bruton Tyrosine Kinase) Inhibitors
Fleming, M. R., Xiao, L., Jackson, K. D., Beckman, J. A., Barac, A., & Moslehi, J. J. (2021) · Circulation Research · doi:10.1161/circresaha.121.318259 · Cited by 36
Chromosome abnormalities in CML
Hagemeijer, A. (1987) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(87)80034-3 · Cited by 35
Self-citationMutation and Cancer: A Personal Odyssey
Knudson, A. G. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60708-3 · Cited by 41
Whitlock, C. A., & Witte, O. N. (1985) · Advances in immunology · doi:10.1016/s0065-2776(08)60338-7 · Cited by 35
The underestimated role of basophils in Ph + chronic myeloid leukaemia
Valent, P., Horny, H., & Arock, M. (2018) · European Journal of Clinical Investigation · doi:10.1111/eci.13000 · Cited by 35
“Marked basophilia is a pathognomonic feature and a strong prognostic factor in BCR-ABL1+ CML.”
BackgroundInfluentialPonatinib and other CML Tyrosine Kinase Inhibitors in Thrombosis
Zeng, P., & Schmaier, A. H. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21186556 · Cited by 35
“First, experimental hybridization of chromosome 9 Bcr with chromosome 22 Abl1 has been done in mice and patient somatic cells [45].”
BackgroundMolecular Pathogenesis of Gastrointestinal Stromal Tumor: A Paradigm for Personalized Medicine
Dermawan, J. K. T. K., & Rubin, B. P. (2021) · Annual Review of Pathology Mechanisms of Disease · doi:10.1146/annurev-pathol-042220-021510 · Cited by 36
The human c-abl oncogene in the philadelphia translocation
Groffen, J., Stephenson, J. R., Heisterkamp, N., Bartram, C. R., de Klein, A., & Grosveld, G. C. (1984) · Journal of Cellular Physiology · doi:10.1002/jcp.1041210421 · Cited by 36
Self-citationAoki, S., Kong, D., Matsui, K., & Kobayashi, M. (2004) · Anti-Cancer Drugs · doi:10.1097/00001813-200404000-00009 · Cited by 34
Chandra, H. S., Heisterkamp, N., Hungerford, A., Morrissette, J. J. D., Nowell̀, P. C., Rowley, J. D., & Testa, J. R. (2011) · Cancer Genetics · doi:10.1016/j.cancergen.2011.03.002 · Cited by 34
“then showed that the ABL proto-oncogene was present on the Ph chromosome and not on the derivative chromosome 9, indicative of a reciprocal exchange between chromosomes 9 and 22 (37).”
BackgroundSelf-citationChronic myeloid leukemia: Pathophysiology, diagnostic parameters, and current treatment concepts
Sillaber, C., Mayerhofer, M., Agis, H., Sagaster, V., Mannhalter, C., Sperr, W. R., Geissler, K. H., & Valent, P. (2003) · Wiener klinische Wochenschrift · doi:10.1007/bf03041033 · Cited by 34
“This translocation fuses the abl gene on chromsome 9 to the bcr gene on chromosome 22, thereby creating the bcr/abl-oncogene [3, 4].”
BackgroundOncogenes: Implications for the Diagnosis and Treatment of Cancer
Cline, M. J., SLAMON, D. J., & Lipsick, J. S. (1984) · Annals of Internal Medicine · doi:10.7326/0003-4819-101-2-223 · Cited by 34
Youngman, S., Bates, G. P., Williams, S., McClatchey, A. I., Baxendale, S., Sedláček, Z., Altherr, M. R., Wasmuth, J. J., MacDonald, M. E., Gusella, J. F., et al. (1992) · Genomics · doi:10.1016/s0888-7543(05)80225-3 · Cited by 34
Telerman, A., Amson, R. B., Zakut, R., & Givol, D. (1988) · Molecular and Cellular Biology · doi:10.1128/mcb.8.4.1498 · Cited by 34
Dan, S., Naito, M., Seimiya, H., Kizaki, A., Mashima, T., & Tsuruo, T. (1999) · Oncogene · doi:10.1038/sj.onc.1202423 · Cited by 34
“…et al., 1997). c-Abl was originally identi®ed as a cellular counterpart of the v-Abl transforming gene of Abelson murine leukemia virus (A-MuLV) (de Klein et al., 1982) and is activated by certain DNA damaging agents, such as IR, UV, cisplatin, 1-b-D-arabinofuranosylcytosine (ara-C) and mitomycin…”
BackgroundTyrosine phosphorylation of P160 BCR by P210 BCR-ABL
Lu, D., Liu, J., Campbell, M., Guo, J., Heisterkamp, N., Groffen, J., Canaani, E., & Arlinghaus, R. B. (1993) · Blood · doi:10.1182/blood.v82.4.1257.1257 · Cited by 34
Self-citationOncogenes, cancer and analytical cytology
Watson, J. V. (1986) · Cytometry · doi:10.1002/cyto.990070503 · Cited by 34
Translocation breakpoint mapping: Molecular and cytogenetic studies of chromosome 22
Emanuel, B. S., Nowell̀, P. C., McKeon, C., Croce, C. M., & Israel, M. A. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90375-4 · Cited by 34
Salesse, S., & Verfaillie, C. M. (2003) · PubMed · Cited by 33
Characterization of the BCR Promoter in Philadelphia Chromosome-Positive and -Negative Cell Lines
Shah, N. P., Witte, O. N., & Denny, C. T. (1991) · Molecular and Cellular Biology · doi:10.1128/mcb.11.4.1854 · Cited by 33
Zeng, Y., Graner, M. W., Feng, H., Li, G., & Katsanis, E. (2004) · International Journal of Cancer · doi:10.1002/ijc.20115 · Cited by 35
Dunant, N., Wisniewski, D. J., Strife, A., Clarkson, B., & Resh, M. D. (2000) · Cellular Signalling · doi:10.1016/s0898-6568(00)00073-5 · Cited by 38
Wognum, A. W., Jong, M. O. D., & Wagemaker, G. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609045710 · Cited by 34
Detection of Chromosomal Translocations :in Leukemia-Lymphoma Cells by Polymerase Chain Reaction
Drexler, H. G., Borkhardt, A., & Janssen, J. W. G. (1995) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199509112194 · Cited by 34
The N-rasoncogene assigned to the short arm of human chromosome 1
de Martinville, B., Cunningham, J. M., Murray, M. J., & Francke, U. (1983) · Nucleic Acids Research · doi:10.1093/nar/11.15.5267 · Cited by 33
Wang, Y., He, Y., Shi, Y., Qian, D. C., Gray, K. J., Winn, R. A., & Martin, A. R. (2024) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2024.04.002 · Cited by 38
Lee, J. P., Birnstein, E., Masiello, D., Yang, D., & Yang, A. S. (2009) · Journal of Hematology & Oncology · doi:10.1186/1756-8722-2-30 · Cited by 32
“CML is a clonal myeloproliferative malignancy caused by a specific chromosomal translocation involving chromosomes 9 and 22, giving rise to the "Philadelphia Chromosome," which fuses the two genes bcr and abl [9-14].”
BackgroundPeschel, C., Aulitzky, W. E., & Huber, C. G. (1996) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199609074370 · Cited by 32
A new partner gene fused to ABL1 in a t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia
Braekeleer, E. D., Douet‐Guilbert, N., Bris, M. ‐. L., Berthou, C., Morel, F., & Braekeleer, M. D. (2007) · Leukemia · doi:10.1038/sj.leu.2404773 · Cited by 31
Sequencing Strategies for Fusion Gene Detection
Heyer, E. E., & Blackburn, J. (2020) · BioEssays · doi:10.1002/bies.202000016 · Cited by 32
c‐MYC Impairs Immunogenicity of Human B Cells
Schlee, M., Schuhmacher, M., Hölzel, M., Laux, G., & Bornkamm, G. W. (2007) · Advances in cancer research · doi:10.1016/s0065-230x(06)97007-9 · Cited by 32
Sillaber, C., Mayerhofer, M., Aichberger, K. J., Krauth, M. T., & Valent, P. (2004) · European Journal of Clinical Investigation · doi:10.1111/j.0960-135x.2004.01365.x · Cited by 36
Čejková, P., Zettl, A., Baumgärtner, A. K., Chott, A., Ott, G., Müller‐Hermelink, H. K., & Starostik, P. (2005) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-005-1214-6 · Cited by 34
“ABL1 is a ubiquitously expressed tyrosine kinase that is fused to BCR in CML and precursor B-ALL cases with the t (9;22)(q34;q11) translocation [6, 7], to ETV6 in leukemias with the t(9;12)(q34;p13) translocation [11] and toNUP214 in episomes consisting of ABL1 and NUP214 amplicons in T-cell acute lymphoblastic leukem…”
BackgroundThe human c-Ha-ras2 is a processed pseudogene inactivated by numerous base substitutions
Miyoshi, J., Kagimoto, M., Soeda, E., & Sakaki, Y. (1984) · Nucleic Acids Research · doi:10.1093/nar/12.4.1821 · Cited by 32
Herzog, R. M., Lutz, S., Blin, N., Marasa, J. C., Blinder, M. A., & Tollefsen, D. M. (1991) · Biochemistry · doi:10.1021/bi00219a027 · Cited by 31
Enrique, P. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90201-8 · Cited by 31
Sandberg, A. A., Morgan, R., Kipps, T. J., Hecht, B. K., & Hecht, F. (1985) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(85)90210-9 · Cited by 31
Oncogenes: cause or consequence in the development of glial tumors
Akbaşak, A., & Akbaşak, B. S. (1992) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(92)90060-x · Cited by 31
Elefanty, A. G., & Cory, S. (1992) · Blood · doi:10.1182/blood.v79.5.1271.bloodjournal7951271 · Cited by 31
Fioretos, T. (2015) · Wiley eBooks · doi:10.1002/9781118795569.ch8 · Cited by 31
Allosteric Inhibition of ABL Kinases: Therapeutic Potential in Cancer
Jones, J. K., & Thompson, E. M. (2020) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-20-0069 · Cited by 34
Antiproliferative Effect of Aaptamine on Human Chronic Myeloid Leukemia K562 Cells
Jin, M., Zhao, W., Zhang, Y., Kobayashi, M., Duan, H., & Kong, D. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12117352 · Cited by 30
“Chronic myelogenous leukemia (CML) is a myeloproliferative disease originating from a constitutively active tyrosine kinase termed Bcr-Abl, which is expressed by an oncogene resulting from a reciprocal translocation between chromosome 9 and chromosome 22 [1].”
BackgroundWhy should cell biologists study microbial pathogens?
Welch, M. D. (2015) · Molecular Biology of the Cell · doi:10.1091/mbc.e15-03-0144 · Cited by 36
“It was also soon recognized that the human ABL1 gene, which encodes c-Abl, participates in the Philadelphia chromosomal translocation, which is commonly associated with leukemias (de Klein et al., 1982).”
BackgroundChiorean, E. G., Dylla, S. J., Olsen, K., Lenvik, T. R., Soignier, Y., & Miller, J. S. (2003) · Blood · doi:10.1182/blood-2002-04-1172 · Cited by 30
Psychosocial outcome in a randomized surgical trial for treatment of primary breast cancer
Kemeny, M. M., Wellisch, D. K., & Schain, W. S. (1988) · Cancer · doi:10.1002/1097-0142(19880915)62:6<1231::aid-cncr2820620631>3.0.co;2-8 · Cited by 168
Kozbor, D., Giallongo, A., Sierzega, M. E., Konopka, J. B., Witte, O. N., Showe, L. C., & Croce, C. M. (1986) · Nature · doi:10.1038/319331a0 · Cited by 30
Morris, C. M., Honeybone, L., Hollings, P. E., & Fitzgerald, P. H. (1989) · Blood · doi:10.1182/blood.v74.5.1768.1768 · Cited by 30
Willecke, K., & Sch�fer, R. (1984) · Human Genetics · doi:10.1007/bf00286587 · Cited by 30
Precision medicine in myeloid malignancies
Westermann, J., & Bullinger, L. (2021) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2021.03.034 · Cited by 30
H. pyloriselectively blocks EGFR endocytosis via the non-receptor kinase c-Abl and CagA
Bauer, B., Bartfeld, S., & Meyer, T. F. (2008) · Cellular Microbiology · doi:10.1111/j.1462-5822.2008.01246.x · Cited by 29
“It is still unknown whether c-Abl triggers additional host cell responses besides the promotion of cell scattering and cell motility (Poppe et al., 2007; Tammer et al., 2007). c-Abl is a key factor involved in human myelocytic leukaemia (de Klein et al., 1982).”
BackgroundYan, T., Hu, G., Wang, A., Sun, X., Yu, X., & Jia, J. (2018) · Phytotherapy Research · doi:10.1002/ptr.6029 · Cited by 29
“Chronic myeloid leukemia (CML) is a myeloproliferative disorder characterized by BCRABL fusion gene (Cai et al., 2012; De Klein et al., 1982).”
BackgroundKaur, G., Narayanan, V. L., Risbood, P. A., Hollingshead, M. G., Stinson, S. F., Varma, R. K., & Sausville, E. A. (2005) · Bioorganic & Medicinal Chemistry · doi:10.1016/j.bmc.2004.12.003 · Cited by 29
Niederle, N., Kloke, O., Wandl, U. B., Becher, R., Moritz, T., & Opalka, B. (1993) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428199309148513 · Cited by 29
Sivachenko, A., & Yuryev, A. (2007) · Expert Opinion on Therapeutic Targets · doi:10.1517/14728222.11.3.411 · Cited by 29
“A chromosomal abnormality, the Philadelphia chromosome (Ph), was associated with CML as early as 1960 [16], and it took almost 25 years to identify the actual genes flanking the translocation breakpoint [17,18].”
BackgroundDuplication of thebcrand gamma-glutamyl transpeptidase genes
Heisterkamp, N., & Groffen, J. (1988) · Nucleic Acids Research · doi:10.1093/nar/16.16.8045 · Cited by 29
Self-citationWestbrook, C. A., Beau, M. M. L., Dı́az, M. O., Groffen, J., & Rowley, J. D. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.24.8742 · Cited by 29
Self-citationMorris, C. M., Rosman, I., Archer, S. A., Cochrane, J. M., & Fitzgerald, P. H. (1988) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(88)90240-3 · Cited by 29
Low level of DNA repair in human chromosome 1 heterochromatin
Surrallés, J., Darroudi, F., & Natarajan, A. T. (1997) · Genes Chromosomes and Cancer · doi:10.1002/(sici)1098-2264(199710)20:2<173::aid-gcc8>3.0.co;2-0 · Cited by 50
Turker, M. S., Smith, A. C., & Martin, G. M. (1984) · Somatic Cell and Molecular Genetics · doi:10.1007/bf01534473 · Cited by 29
Bartram, C. R., de Klein, A., Hagemeijer, A., Carbonell, F., Kleihauer, E., & Grosveld, G. C. (1986) · Leukemia Research · doi:10.1016/0145-2126(86)90045-7 · Cited by 29
Self-citationDow, L. W., Tachibana, N., Raimondi, S. C., Lauer, S. J., Witte, O. N., & Clark, S. (1989) · Blood · doi:10.1182/blood.v73.5.1291.1291 · Cited by 29
Groffen, J., & Heisterkamp, N. (1997) · Baillière s Clinical Haematology · doi:10.1016/s0950-3536(97)80002-9 · Cited by 28
Self-citationBCR-ABL Is Not an Immunodominant Antigen in Chronic Myelogenous Leukemia
Grünebach, F., Mirakaj, V., Mirakaj, V., Müller, M., Brümmendorf, T. H., & Brossart, P. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2868 · Cited by 30
Use of molecular probes in the study of endocrine diseases
Lloyd, R. V. (1987) · Human Pathology · doi:10.1016/s0046-8177(87)80402-1 · Cited by 28
Gordon, H. (1985) · Mayo Clinic Proceedings · doi:10.1016/s0025-6196(12)60746-0 · Cited by 33
DNA aneuploidy in adult acute leukemia
Barlogie, B., Stass, S. A., Dixon, D. O., Keating, M. J., Cork, A., Trujillo, J. M., McCredie, K. B., & Freireich, E. J. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90207-x · Cited by 28
Takahashi, R., Mihara, K., Maeda, S., Yamaguchi, T., Chen, H., Aoyama, N., MURAO, S., Hatanaka, M., & Sugiyama, T. (1986) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.83.4.1079 · Cited by 28
Increased expression of a novel c-abl-related RNA in K562 cells
Leibowitz, D. S., Cubbon, R., & Bank, A. (1985) · Blood · doi:10.1182/blood.v65.3.526.526 · Cited by 28
Delayed Complications After Hematopoietic Cell Transplantation
Flowers, M. E. D., & Deeg, H. J. (2003) · Wiley eBooks · doi:10.1002/9780470987070.ch69 · Cited by 28
The cytogenetics of Wilms' tumor
Slater, R. M. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90369-9 · Cited by 28
C-sis and C-abl expression in chronic myelogenous leukemia and other hematologic malignancies
Romero, P., Blick, M. B., Talpaz, M., Murphy, E., Hester, J. P., & Gutterman, J. (1986) · Blood · doi:10.1182/blood.v67.3.839.839 · Cited by 28
Reiter, A., Skladny, H., Hochhaus, A., Seifarth, W., Heimpel, H., Bartram, C. R., Cross, N. C. P., & Hehlmann, R. (1997) · British Journal of Haematology · doi:10.1046/j.1365-2141.1997.32645.x · Cited by 28
“Exposure was carried out for several days at ¹708C (de Klein et al, 1982).”
BackgroundSelf-citationThe prognostic and therapeutic potential of HO-1 in leukemia and MDS
Sadeghi, M. R., Fathi, M., Navashenaq, J. G., Mohammadi, H., Yousefi, M., Hojjat‐Farsangi, M., Namdar, A., Akbari, A. A. M., & Jadidi‐Niaragh, F. (2023) · Cell Communication and Signaling · doi:10.1186/s12964-023-01074-8 · Cited by 28
Trisomy 6 as a Primary Karyotypic Aberration in Hematologic Disorders
Mohamed, A. N., Varterasian, M. L., Dobin, S. M., McConnell, T. S., Wolman, S. R., Rankin, C. J., Willman, C. L., Head, D. R., & Slovak, M. L. (1998) · Cancer Genetics and Cytogenetics · doi:10.1016/s0165-4608(98)00057-0 · Cited by 27
Translocation Breakpoints Preferentially Occur in Euchromatin and Acrocentric Chromosomes
Lin, C., Shukla, A., Grady, J. P., Fink, J. L., Dray, E. V., & Duijf, P. H. G. (2018) · Cancers · doi:10.3390/cancers10010013 · Cited by 34
“Second, not surprisingly, with 18.8% and 7.4% of all translocations, t(9;22)(q34;q11) and t(8;21)(q22;q22)—corresponding to the Philadelphia chromosome/BCR-ABL1 and RUNX1-RUNX1T1/AML1-ETO fusion genes [12,15]—were the most frequent translocations in blood cancers (Figure 6d, Supplementary Figure S1, Table S2).”
BackgroundInfluentialMendoza, F. A., Piera-Velázquez, S., & Jiménez, S. A. (2021) · Translational research · doi:10.1016/j.trsl.2021.01.001 · Cited by 29
Multiple molecular abnormalities in Ph1 chromosome positive acute lymphoblastic leukaemia
Dreazen, O., Klisak, I. J., Jones, G., Ho, W. G., Sparkes, R. S., & Gale, R. P. (1987) · British Journal of Haematology · doi:10.1111/j.1365-2141.1987.tb02353.x · Cited by 27
Kong, D., Aoki, S., Sowa, Y., Sakai, T., & Kobayashi, M. (2008) · Marine Drugs · doi:10.3390/md20080023 · Cited by 27
“Chronic myelogenous leukemia (CML) is a hematopoietic stem cell cancer caused by the Bcr-Abl tyrosine kinase which arised from Philadelphia chromosome (Ph) translocation [1,2].”
BackgroundGuilhot, F., & Roy, L. (2004) · CRC Press eBooks · doi:10.1201/b14440-42 · Cited by 27
Differential growth patterns in SCID mice of patient-derived chronic myelogenous leukemias
McGuirk, J. P., Yan, Y., Childs, B. H., Fernandez, J., Barnett, L., Jagiello, C., Collins, N., & O’Reilly, R. (1998) · Bone Marrow Transplantation · doi:10.1038/sj.bmt.1701343 · Cited by 27
Ferrero, D., & Royera, G. (1984) · Clinics in Haematology · doi:10.1016/s0308-2261(21)00433-1 · Cited by 27
Singh, S., Wass, J., Vincent, P. C., Young, G. A. R., & Gunz, F. W. (1986) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(86)90002-6 · Cited by 27
“Recent studies have shown that a) the t(9:22) is reciprocal [2] and associated with transfer of the c-abl oncogene from chromosome #9 to #22 [15]; b) the breakpoints on chromosome #22 occur within a limited region [16]; c) a novel 8 kb RNA transcript in CGL is the result of transcription from c-abl and part of the bre…”
BackgroundTreatment of chronic myelogenous leukemia with recombinant interferon alfa-2b
Niederle, N., Kloke, O., May, D., Becher, R., Osieka, R., & Schmidt, C. G. (1987) · Investigational New Drugs · doi:10.1007/bf00207259 · Cited by 27
Diagnostic utility of oncogenes and their products in human cancer
McKenzie, S. J. (1991) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(91)90014-c · Cited by 32
Alon, Y., Hämmerling, G. J., Segal, S., & Bar‐Eli, M. (1987) · PubMed · Cited by 27
Targeting Protein Kinases for Tumor Therapy
Sachsenmaier, C. (2001) · Oncology Research and Treatment · doi:10.1159/000055106 · Cited by 38
Aichberger, K. J., Mayerhofer, M., Vales, A., Krauth, M., Gleixner, K. V., Bilban, M., Esterbauer, H., Sonneck, K., Florian, S., Derdak, S. V., et al. (2006) · Blood · doi:10.1182/blood-2005-12-028456 · Cited by 26
Induction of BCR‐ABL Fusion Genes by in vitro X‐irradiation
Ito, T., Seyama, T., Mizuno, T., Hayashi, T., Iwamoto, K. S., Dohi, K., Nakamura, N., & Akiyama, M. (1993) · Japanese Journal of Cancer Research · doi:10.1111/j.1349-7006.1993.tb02840.x · Cited by 26
Gramatzki, M., Bartram, C., Muller, D., Walter, M. J., Tittelbach, H., & Kalden, J. (1987) · Blood · doi:10.1182/blood.v69.4.1082.1082 · Cited by 26
Self-citationLionberger, J. M., & Smithgall, T. E. (2000) · PubMed · Cited by 26
Koller, C. A., Campbell, V. W., Polansky, D. A., Mulhern, A. I., & Miller, D. M. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111970 · Cited by 26
“A protooncogene, cabl, the cellular homologue of the transforming sequence of the Abelson murine leukemia virus (8), is ordinarily located on chromosome 9q34 (9) and becomes translocated to chromosome 22 with the Ph' translocation (10).”
BackgroundRowley, J. D. (2013) · Science · doi:10.1126/science.1241318 · Cited by 27
Integrating proteomics into precision oncology
Wahjudi, L. W., Bernhardt, S., Abnaof, K., Horak, P., Kreutzfeldt, S., Heining, C., Borgoni, S., Becki, C., Berg, D., Richter, D., et al. (2020) · International Journal of Cancer · doi:10.1002/ijc.33301 · Cited by 32
Spaeny-Dekking, E. H. A., van der Velden, V. H. J., Böttcher, S., Brüggemann, M., Sonneveld, E., Koning-Goedheer, A., Boeckx, N., Lúcio, P., Sędek, Ł., Szczepański, T., et al. (2010) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2010.09.010 · Cited by 25
Chronic myeloid leukaemia: the evolution of gene‐targeted therapy
Joske, D. J. L. (2008) · The Medical Journal of Australia · doi:10.5694/j.1326-5377.2008.tb02027.x · Cited by 25
Ohyashiki, K., Ohyashiki, J. H., Kinniburgh, A. J., Rowe, J. M., Miller, K. B., Raza, A., Preisler, H. D., & Sandberg, A. A. (1987) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(87)90138-5 · Cited by 25
Molecular analysis of a myxoid chondrosarcoma with rearrangements of chromosomes 10 and 22
Shen, W.-P. V., Young, R. F., Walter, B. N., Choi, B. H., Smith, M., & Katz, J. (1990) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(90)90084-n · Cited by 25
Kurahashi, H., Akagi, K., Karakawa, K., Nakamura, T., Dumanski, J. P., Sano, T., Okada, S., Takai, S.-I., & Nishisho, I. (1994) · Human Genetics · doi:10.1007/bf00212017 · Cited by 25
Amiel, A., Yarkoni, S., Slavin, S., Or, R., Lorberboum‐Galski, H., Fejgin, M. D., & Nagler, A. (1994) · Cancer Genetics and Cytogenetics · doi:10.1016/0165-4608(94)90073-6 · Cited by 25
Chronic leukemias: oncogenes, chromosomes, and advances in therapy.
Champlin, R. E., Gale, R., Foon, K. A., & Golde, D. (1986) · Annals of Internal Medicine · doi:10.7326/0003-4819-104-5-671 · Cited by 20
Metadata
- Authors
- Klein, A. D., Kessel, A. G. V., Grosveld, G., Bartram, C. R., Hagemeijer, A., Bootsma, D., Spurr, N. K., Heisterkamp, N., Groffen, J., & Stephenson, J. R.
- Affiliations
- Erasmus University Rotterdam (NL)
- National Cancer Institute (US)
- Venue
- Nature
- Published
- 1982-12
- Volume
- 300
- Issue
- 5894
- Pages
- 765-767
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2060833726
- Cited by
- 1,378
- References
- 27
- Citations by year
- 2026: 8 · 2025: 6 · 2024: 17 · 2023: 12 · 2022: 25 · 2021: 17 · 2020: 18 · 2019: 15 · 2018: 23 · 2017: 28 · 2016: 24 · 2015: 33 · 2014: 16 · 2013: 26 · 2012: 33
- FWCI
- 50.65
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Chronic Myeloid Leukemia Treatments
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and Retrovirus Studies
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Genetics › Genomic variations and chromosomal abnormalities
- Keywords
- Philadelphia chromosome, chromosome 9, chromosome 22, reciprocal translocation, cellular oncogenes, somatic cell hybrids
- MeSH terms
- Chromosomes, Human, 21-22 and Y, Chromosomes, Human, 6-12 and X, DNA, Neoplasm, Gene Expression Regulation, Humans, Leukemia, Myeloid, Oncogenes, Translocation, Genetic
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.